Completed PHASE1 INTERVENTIONAL 4-arm NCT02405520

Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years

Sponsor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Conditions Condylomata Acuminata

Interventions Aluminium Adjuvant high dosage HPV Vaccine low dosage HPV Vaccine medium dosage HPV Vaccine

Updated 12 times since 2017 Last updated: May 23, 2022 Started: Mar 26, 2015 Primary completion: Jun 5, 2019 Completion: May 20, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Condylomata Acuminata and is currently completed. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Mar 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1
Jan 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE1

▶ Show 7 earlier versions

Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
May 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE1
Jan 2020 — May 2020 [monthly]

Active Not Recruiting PHASE1
Sep 2018 — Jan 2020 [monthly]

Active Not Recruiting PHASE1

Status: Unknown Status → Active Not Recruiting
Jun 2018 — Sep 2018 [monthly]

Unknown Status PHASE1
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Jun Zhang
Xiamen Innovax Biotech Co., Ltd

Data source: Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.